Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: Role of kinins

Journal of Cardiac Failure

Volumn 3, Issue 2, 1997, Pages 133-148

  Tschöpe, Garsten ^a   Gohlke, Peter ^b   Zhu, Yi Zhun ^b   Linz, Wolfgang ^c   Schölkens, Bernward ^c   Unger, Thomas ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c SANOFI   (France)

Author keywords

Angiotensin; Angiotensin converting enzyme inhibitors; Bradykinin; Cardiovascular protection; Heart; Icatibant; Kallikrein kinin system; Kinins

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KININ; PHOSPHOTRANSFERASE;

ANIMAL; DRUG EFFECT; HEART; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HEART; HEART VENTRICLES; HUMANS; HYPERTENSION; KALLIKREIN-KININ SYSTEM; KININS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PHOSPHOTRANSFERASES;

EID: 0031155256     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(97)90047-6     Document Type: Review

References (192)

1. Bhoola KD, Figuero CD, Worthy K: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80
2. Linz W, Wiemer G, Gohlke P, Unger TH, Schölkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49
3. Margolius HS: Kallikreins and kinins: molecular characteristics and cellular and tissue responses. Diabetes 1996; 45(suppl 1):S14-9
4. Hecker M, Pörsti I, Bara AT, Busse R: Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at receptor level. Br J Pharmacol 1994;111:238-44
5. Hecker M, Bara AT, Busse R: Potentiation of the biological efficacy of bradykinin by ACE inhibitors: a shift in the affinity of the B2 receptor? Immunopharmacology 1996;33:93-4
6. De Freitas FM, Farraco EZ, de Azevedo DF: General circulatory alterations induced by intravenous infusion of synthetic bradykinin in man. Circulation 1964;29:66-70
7. Willis LR, Luden JH, Hook JB, Williamson HE: Mechanism of natriuretic action of bradykinin. Am J Physiol 1969;217:1-5
8. Levinsky NG: The renal kallikrein-kinin system. Circ Res 1979;44:441-51
9. Armstrong D, Jepson JB, Keele CS Stewart JW: Development of pain-producing substances in human plasma. Nature 1954;174:791-2
10. Armstrong D: Pain. Handb Exp Pharmacol 1970;25: 434-81
11. Scicli AG, Mindrooiu T, Scicli G, Carretero OA: Blood kinins, their concentrations in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin Med 1982;100: 81-93
12. Shimamoto K, Ando T, Tanaka S, Nakahashi Y, Nishitani T, Hosoda S, Ishida H, Iimura O: An improved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. Endocrinol Jpn 1982;29: 487-94
13. Farhy RD, Carretero OA, Ho K-L, Scicli AG: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993;72:1202-10
14. Becker RHA, Wiemer G, Linz W: Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991;18(suppl 2):S110-5
15. Schölkens BA, Linz W, König W: Effects of the angiotensin-converting enzyme inhibitor, ramipril, in isolated ischemic rat heart are abolished by a bradykinin antagonist. J Hypertens 1988;6(suppl 4):25-8
16. Ertl G, Kloner RA, Alexander RW, Braunwald E: Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40-8
17. Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ: Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984;6:1043-7
18. Ertl G: Angiotensin-converting enzyme inhibitors and ischemic heart disease. Eur Heart J 1988;9:716-27
19. Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA: Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990; 182: 395-6
20. Lefer AM, Peck RC: Cardioprotective effects of enalapril in acute myocardial ischemia. Pharmacology 1984;29: 61-9
21. Hock CE, Ribeiro GT, Lefer AM: Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J 1985;109:222-8
22. Stauss HM, Zhu YC, Redlich T, Unger Th: Early and late treatment of infarction-induced heart failure with a converting enzyme inhibitor: bradykinin potentiation versus angiotensin II reduction. Hypertension 1993;22:429 (abstr)
23. Stauss HM, Zhu YC, Redlich TH, Adamiak D, Moot A, Unger TH: Mechanism involved in the reduction of infarct size by ACE inhibition after left coronary ligation in rats. J Hypertens 1994;12(suppl 13):S2 (abstr)
24. Stauss HM, Zhu YC, Redlich TH, Adamiak D, Mott A, Kregel K, Unger TH: ACE inhibitors in infarct induced heart failure: bradykinin versus angiotensin II. J Cardiovasc Risk 1994;1:255-62
25. Duncan AM, Burell LM, Kladis A, Campbell DJ: Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. J Cardiovasc Pharmacol 1996;28:746-54
26. Linz W, Schölkens BA: A specific B2-bradykinin receptor antagonist Hoe 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-2
27. Gohlke P, Linz W, Schölkens BA, Küwer I, Bartenbach S, Schnell A, Unger TH: Angiotensin converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension 1994;23:411-8
28. Unger TH, Mattfeld T, Lamberty V, Bock P, Mall G, Linz W, Schölkens BA, Gohlke P: Effect of early-onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 1992;20:478-82
29. Gohlke P, Küwer I, Schnell A, Amann K, Mall G, Unger T: Bradykinin B2-receptor blockade prevents the increase in capillary growth density induced by chronic ACE inhibitor treatment in SHRSP. Hypertension 1997;29: 478-82
30. Mall G, Zimmer G, Baden S, Mattfeld T: Capillary neoformation in the rat heart: stereological studies on papillary muscles in hypertrophy and physiologic heart. Basic Res Cardiol 1990;85:531-40
31. Carretero OA, Scicli AG: Kinins paracrine hormone. Kidney Int 1988;34(suppl 26):52-9
32. Carretero OA, Scicli AG: The renal kallikrein-kinin system. Am J Physiol 1980;238:247-55
33. Kaplan AP: Mechanisms of bradykinin generation in human plasma. Mon Allergy 1983;18:272-6
34. Mayfield RK, Margolius HS: Renal kallikrein-kinin system. Am J Nephrol 1983;3:145-55
35. Müller-Esterl W, Iwanaga S, Nakanishi S: Kininogens revisited. Trends Biochem Sci 1986;11:336-9
36. De La Cadena AR, Colman RW: Structure and functions of human kininogens. Trends Biochem Sci 1991;12:272-5
37. Frey EK, Kraut H, Werle E, Vogel R, Zickgraf-Rüdel G, Trautschold I: Das Kallikrein-Kinin-System und seine Inhibitoren 1968. F. Enke, Stuttgart
38. Werle E, Maier L: Über die chemische und pharmakologische Unterscheidung von Kallikreinen verschiedener Herkunft. Biochem Z 1952;323:279-88
39. Rabito SF, Scicli AG, Carretero OA: Immunoreactive glandular kallikrein in plasma. In Gross F, Vogel GF: Enzymatic release of vasoactive peptides. Raven Press, New York, 1980
40. Geiger R, Clausnitzer B, Fink E, Fritz H: Isolation of an enzymatically active glandular kallikrein from human plasma by immunoaffinity chromatography. Hoppe Seyler's Z Physiol Chem 1980;361:1795-803
41. Carbini LA, Scicli AG, Carretero OA: The molecular biology of the kallikrein-kinin system: III. The human kallikrein gene family and kallikrein substrate. J Hypertens 1993;11:893-8
42. Carretero OA, Carbini LA, Scicli AG: The molecular biology of the kallikrein-kinin system: I. General description, nomenclature and the mouse gene family. J Hypertens 1993;11:693-7
43. Scicli AG, Carbini LA, Carretero OA: The molecular biology of the kallikrein-kinin system: II. The rat gene family. J Hypertens 1993;11:775-80
44. Spragg J, Austen KF: Plasma factors: the Hageman-factor-dependent pathways and the complement sequence. In Hadden JW, Coffey RG, Spreafico F: Immunopharmacology. Plenum, New York, 1977
45. Sundsmo JS, Fair DS: Relationships among the complement, kinin, coagulation and fibrinolytic systems in the inflammatory reaction. Clin Physiol Biochem 1983;1: 225-84
46. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG: A local kallikrein-kinin system is present in hearts. Hypertension 1994;23:919-23
47. Vio CP, Loyola S, Velarde V: Localization of components of the kallikrein-kinin system in the kidney: relation to renal function. State of the art lecture. Hypertension 1992;19(suppl 2):II10-6
48. Nolly H, Scicli AG, Scicli G, Carretero MA: Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein. Circ Res 1985;56:816-21
49. Nolly H, Carretero OA, Scicli AG: Kallikrein release by vascular tissue. Am J Physiol 1993;265:H1209-14
50. Chao J, Woodley C, Chao L, Margolius HS: Identification of tissue kallikrein in brain and in cell-free translation product encoded by brain mRNA. J Biol Chem 1983; 258:15173-8
51. Schachter M, Peret MW, Billing AG, Wheeler GD: Immunolocalization of the protease kallikrein in the colon. J Histochem Cytochem 1983;31:1255-60
52. Chao J, Chao L, Margolius HS: Isolation of tissue kallikrein in rat spleen by monoclonal antibody-affinity chromatography. Biochem Biophys Acta 1984;801: 244-9
53. Sealey JE, Atlas ST, Laragh JH, Oza NB, Ryan JW: Human urinary kallikrein converts inactive renin and is a possible physiological activator of renin. Nature 1978; 275:144-5
54. Campbell DJ, Kladis A, Duncan AM: Bradykinin peptides in kidney, blood and other tissues of the rat. Hypertension 1993;21:155-65
55. Girey GJD, Talamo RC, Colman RW: The kinetics of the release of bradykinin by kallikrein in normal human plasma. J Lab Clin Med 1972;80:496-507
56. Talamo RC: Kinetics of kinin release and disappearance. In Pisano JJ, Austen KF: Fogarty International Center Proceedings: Chemistry and biology of the kallikrein-kinin system in health and disease. 1977, Bethesda, MD
57. Ryan JW, Robelero J, Stewart JM: Inactivation of bradykinin in the pulmonary circulation. Biochem J 1968; 110:795-7
58. Erdös EG, Yang HYT: Kininases. In Erdös EG: Handbook of experimental pharmacology XXV. Springer-Verlag, New York, 1979
59. Skidgel RA, Schulz WW, Tam LT, Erdös EG: Human renal angiotensin I converting enzyme and neutral endopeptidase. Kidney Int 1987;20(suppl):S45-46
60. Regoli D, Barabé J: Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980;32:1-6
61. Hess JF, Borkowski JA, Young GS, Strader CD, Ransom RW: Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 1992;184:260-8
62. Ma J-X, Wang D-Z, Chao L, Chao J: Cloning, sequence analysis and expression of the gene encoding the mouse bradykinin B2 receptor. Gene 1994;149:283-8
63. 1 bradykinin receptor. J Biol Chem 1994;264:21583-6
64. 2 receptor gene. J Biol Chem 1994;269: 26920-5
65. Pesquero JB, Pesquero JL, Oliviera SM, Röscher AA, Metzger R, Ganten D, Bader M: Molecular cloning and functional characterization of a mouse bradykinin B1 receptor gene. Biochem Biophys Res Commun 1996;220:219-25
66. Maeceau F: Kinin Bl receptors: a review. Immunopharmacology 1995;30(1):1-26
67. Vavrek RJ, Stewart JM: Competitive antagonists of bradykinin. Peptides 1985;6:161-4
68. Waeber B, Aubert JF, Vavrek RJ, Stewart JM, Nussberger J, Brunner HR: Role of bradykinin in blood pressure regulation of conscious spontaneously hypertensive rats. J Hypertens 1986;4(suppl 6):S597-8
69. Aubert JF, Waeber B, Nussberger J, Vavrek RJ, Stewart JM, Brunner HR: Lack of a role of circulating bradykinin in the blood pressure response to acute angiotensin converting enzyme inhibition in rats. Agents Actions 1987; 22:349-54
70. Mulinari R, Benetos A, Gavras I, Gavras H: Vascular and sympathoadrenal response to bradykinin and a bradykinin analogue. Hypertension 1988;11:754-7
71. Bao G, Qadri F, Stauss B, Stauss H, Gohlke P, Unger TH: HOE 140, a new highly potent and long acting bradykinin antagonist in conscious rats. Eur J Pharmacol 1992; 200:179-82
72. Hock FJ, Wirth K, Linz W, Gerhards HJ, Wiemer G, Henke ST, Breipohl G, König W, Knolle J, Schölkens BA: Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102: 769-73
73. Wirth K, Hock FJ, Albus U, Linz W, Anagnostopoulos H, Henke ST, Breipohl G, König W, Knolle J, Schölkens BA: Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991; 102:774-7
74. Gohlke P, Lamberty V, Küwer T, Bartenbach S, Schnell A, Linz W, Schölkens BA, Wiemer G, Unger Th: Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3′,5′-monophosphate. Hypertension 1993;22:682-7
75. Bao G, Gohlke P, Qadri F, Unger Th: Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992;20:74-9
76. Stewart JM, Géra L, Hanson W, Zuzack JS, Burkard M, McCullough R, Whalley ET: A new generation of bradykinin antagonists. Immunopharmacology 1996;33: 51-60
77. Abelous JE, Bardier E: Les substances hypotensives de l'urine humaine normale. C R Seances Soc Biol 1909; 66:511
78. Frey EK, Kraut H: Ein neues Kreislaufhormon und seine Wirkung. Naunyn-Schmiedeberg's Arch Exp Pathol Pharmakol 1928;133:1-56
79. McCarthy DA, Potter DE, Nicolaides ED: An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. J Pharmacol Exp Ther 1965; 148:117-22
80. Barbé J, Marceau F, Thériault B, Drouin JN, Regoli D: Cardiovascular actions of kinins in the rabbit. Can J Physiol Pharmacol 1979;57:78-91
81. Lamontagne D, Nakhostine N, Couture R, Nadeau R: Mechanism of kinin B preceptor-induced hypotension in the anesthetized dog. J Cardiovasc Pharmacol 1996;28: 645-50
82. Lückhoff A, Busse R, Winter I, Basenge E: Characterization of vascular relaxant factor released from cultured endothelial cells. Hypertension 1987;9:295-303
83. Busse R, Fleming I: Kinin-mediated signal transduction in endothelial cells. In Schölkens BA, Unger Th: ACE inhibitors, endothelial function and atherosclerosis. Media Medica, Amsterdam 1993
84. Hilton SM: The physiological role of glandular kallikreins. Handb Exp Pharmacol 1970;25:389-99
85. Jauch KW, Guenther B, Hartl W, Rett K, Wincklmeyer M, Dietze G: Improvement of impaired postoperative insulin action by bradykinin. Biol Chem Hoppe-Seyler 1986; 367:207-10
86. Nasjletti A, Malik KU: Renal kinin-prostaglandin relationship: implications for renal function. Kidney Int 1981; 19:860-8
87. Collier HOJ: Kinins and ventilation of the lungs. Handb Exp Pharmacol 1970;25:409-20
88. Eisen V: Formation and function of kinins. Rheumatology 1970;3:103-68
89. Margolius HS: Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Annu Rev Pharmacol Toxicol 1989;29:343-64
90. Jaffa AA, Rust PF, Mayfield RK: Kinin, a mediator of diabetes-induced glomerular hyperfiltration. Diabetes 1995;44:156-60
91. Tschöpe C, Gavriluk V, Reinecke A, Seidl U, Riester U, Hilgenfeldt U, Ritz E, Unger Th: Bradykinin excretion is increased in severely hyperglycemic streptozotocin-diabetic rats. Immunopharmacology 1996;33:344-8
92. Kellermeyer RW, Graham RC: Kinins: possible physiologic and pathologic roles in man. N Engl J Med 1968; 279:754-9, 802-7, 859-66
93. Hashimoto K, Hirose M, Furukawa K, Hayakawa H, Kimura E: Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Jpn Heart J 1977;18:679-80
94. Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G: Ramiprilat increases bradykinin outflow from isolated rat hearts. Br J Pharmacol 1993;108: 293-5
95. 9-bradykinin release following reperfusion of the ischemic rat heart. Br J Pharmacol 1995;115:476-8
96. Danckwardt L, Shimizu I, Bönner G, Rettig R, Unger Th: Converting enzyme inhibition in kinin-deficient Brown-Norway rats. Hypertension 1990;16:429-35
97. Bao G, Gohlke P, Unger Th: Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models. J Cardiovasc Pharmacol 1992;20 (suppl 9):S96-9
98. Carbonell FI, Carretero OA, Stewart JM, Scicli AG: Effect of a kinin antagonist on the acute antihypertensive activity of enalapril in severe hypertension. Hypertension 1988;11:239-43
99. Carretero OA, Miyazaki S, Scicli AG: Role of kinins in the acute hypertensive effect of the converting enzyme inhibitor, captopril. Hypertension 1981;3:18-22
100. Cachefiero V, Sakakibara T, Nasjletti A: Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992;19:138-45
101. Mombouli J-V, Vanhautte PM: Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 1995;35:679-705
102. Johnson AR, Schulz WW, Noguiera, Erdös EG: Kinins and angiotensin: angiotensin I converting enzyme (kininase II) in endothelial cells cultured from human pulmonary arteries and veins. Clin Exp Hypertens 1980;2:659-74
103. Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB: The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 1988;263:16327-33
104. Saed GM, Carretero OA, MacDonald JR, Scicli AG: Kallikrein messenger RNA in rat arteries and veins. Circ Res 1990;67:510-16
105. Falkenhahn M, Franke F, Bohle Mr, Zhu YC, Stauss HM, Bachmann S, Danilov S, Unger Th: Cellular distribution of angiotensin converting enzyme after myocardial infarction. Hypertension 1995;25:219-26
106. 2-kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther 1990;252:581-5
107. Derian CK, Moskowitz MA: Polyphosphoinositide hydrolysis in endothelial cells and carotid segments (bradykinin-2 receptor stimulation is calcium-independent). J Biol Chem 1986;261:3831-7
108. Lambert TL, Kent RS, Whorton AR: Bradykinin stimulation of inositol polyphosphate production in porcine aortic endothelial cells. J Biol Chem 1986;261:15288-93
109. Adams DJ, Barakeh J, Laskey R, van Bremen C: Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J 1989;3:2389-2400
110. Wiemer G, Schölkens BA, Becker RHA, Busse R: Rat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-63
111. Gabbiani G, Glemes G, Guelpa C, Valoton MB, Badonnel MC, Huttner I: Morphological and functional changes of the aortic intima during experimental hypertension. Am J Pathol 1979;96:399-426
112. Lüscher TF, Vanhoutte PM, Boulanger C, Dohi Y, Buhler FR: Endothelial dysfunction in hypertension. In Rubanyi G: Cardiovascular significance of endothelium-derived vasoactive factors. Futura, New York, 1991
113. Panza JA, Quyyumio AA, Brush JE, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension N Engl J Med 1990; 323:22-7
114. Linder L, Kiowski W, Bühler FR, Lüscher TF: Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response to essential hypertension. Circulation 1990;81: 1762-7
115. Liang CS, Gavras H, Black J, Sherman LG, Hood WB: Renin-angiotensin system inhibition in acute myocardial infarction in dogs: effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation 1982;66:1249-55
116. Brown EJ, Swinfor RD, Shatkin BJ, Honig SC, Cohn PF: Massive reperfusion injury: paradoxical effect of combined angiotensin-converting enzyme inhibition plus myocardial perfusion. J Am Coll Cardiol 1988;11:50A
117. De Lorgeril M, Ovize M, Delaye G, Renaud S: Importance of the flow perfusion deficit in the response to captopril in experimental myocardial infarction. J Cardiovasc Pharmacol 1992;19:324-9
118. The ARIE Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8
119. Trandopril Cardiac Evaluation (TRACE) Study Group: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl Med 1995;333:1670-6
120. Groves P, Kurz S, Just H, Drexler H: Role of endogenous bradykinin in human coronary vasomotor control. Circulation 1995;12:3424-30
121. Linz W, Schölkens BA, Han YF: Beneficial effects of the converting enzyme inhibitor ramipril in ischemic hearts. J Cardiovasc Pharmacol 1986;8(suppl 10):S91-S99
122. Van Gilst WH, De Graeff PA, Leeuw MJ, Scholtens E Wesseling H: Converting enzyme inhibitors and the role of their sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilators. J Cardiovasc Pharmacol 1991;18:429-36
123. Rosas R, Montague D, Gross M, Bohr DF: Cardiac action of vasoactive polypeptides in the rat. Circ Res 1965; 16:150-61
124. Przyklenk K, Kloner RA: "Cardioprotection" by ACE-inhibitors in acute myocardial ischemia and infarction? Basic Res Cardiol 1993;88(suppl 1): 139-54
125. Smits JFM, van Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJAP: Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharamacol 1992;20:772-8
126. Raya TE, Fonken SJ, Lee RW, Daugherty S, Goldman S, Wong PC, Timmermanns PB, Morkin E: Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model for heart failure. Am J Hypertens 1991;4:334S-340S.
127. Spitznagel H, Stauss HM, Gohlke P, Zhu YZ, Zhu YC, Falkenhahn M, Unger Th: Angiotensin II and bradykinin in hypertensive heart disease and myocardial infarction. High Blood Press 1996;5:119-23
128. Zhu Y-C, Stauss HM, Bao G, Gohlke P, Zhu Y-Z, Redlich Th, Unger Th: Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. Can J Physiol Pharmacol 1995;73:827-31
129. Coller BS: Platelets in cardiovascular thrombosis and thrombolysis. In Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE: The heart and cardiovascular system. Raven Press, New York, 1992, pp. 219-73
130. Linz W, Schölkens BA: Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts. J Cardiovasc Pharmacol 1987; 10(suppl 7):S75-S82
131. Van Gilst WH, de Graeff PA, Wesseling H, de Langen CDJ: Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol 1986;8:722-8
132. Westlin W, Mullane K: Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation 1988;77(suppl I):130-9
133. Przyklenk K, Kloner RA: Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanism of action. Am Heart J 1991;121:1319-30
134. Tio RA, de Langen CDJ, de Graeff PA, van Gilst WH, Bel KJ, Wolters GTP, Mook PH, van Wijngaarden J, Wesseling H: The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drugs Ther 1990;4:695-704
135. Van Wijngaarden J, Tobe TJM, Weersink EGL, Bel KJ, de Graeff, de Langen CDJ, van Gilst WH, Wesseling H: Effects of early angiotensin-converting enzyme inhibition in a pig model of myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 1992;19:408-16
136. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K: Cardioprotection by ACE inhibitor in ischemic heart is independent of local angiotensin II formation. Agents Actions Suppl 1992;38:217-27
137. Hartman JC, Hullinger TG, Wall MT, Shebuski JR: Reduction of myocardial infarct size is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 1993;234:229-36
138. Hartman JC, Wall TM, Hullinger TG, Shebuski JR: Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003
139. Liu Y-H, Yang X-P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA: Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996;27:7-13
140. Pfeffer JM, Fischer TA, Pfeffer MA: Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. Annu Rev Physiol 1995; 57:805-26
141. Sadochima JS, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1991; 73:413-23
142. Fabris B, Jackson B, Kohzuki M, Perich R, Johnston CI: Increased cardiac angiotensin converting enzyme in rats with chronic heart failure. Clin Exp Pharmacol Physiol 1990;17:309-14
143. Schunkert H, Dzau V, Tang S, Hirsch A, Apstein C, Lorell B: Increased rat angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest 1990;86:1913-20
144. Zhou G, Tyagi SC, Weber KT: Bradykinin regulates collagen turnover in cardiac fibroblasts. Clin Res 1993; 41:630A (abstr)
145. Weber KT: Hormones and fibrosis: a case for lost reciprocal regulation. News Physiol Sci 1994;9:123-8
146. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23(pt 2):869-77
147. Weber KT, Sun Y, Katwa LC, Cleutjens JPM: Connective tissue: a metabolic entity? J Mol Cell Cardiol 1995; 27:107-20
148. De Carvalho Frimm, Sun Y, Weber KT: Wound healing following myocardial infarction in the rat: role for bradykinin and prostaglandins. J Mol Cell Cardiol 1996; 28:1279-85
149. Sigusch HH, Campbell SE, Weber KT: Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. Cardiovasc Res 1996;31:546-54
150. McDonald KM, Carlyle PF, Mathews J, Hauer K, Elbers T, Hunter D, Cohn JN: Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. Trans Assoc Am Physicians 1990; 103:229-35
151. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:771-2
152. Grossman W, Lorell H: Hemodynamic aspects of left ventricular remodeling after myocardial infarction. Circulation 1993;87(suppl VII):28-30
153. Raya ET, Gay RG, Aguirre M, Goldman S: Importance of venodilation in prevention of left ventricular dilatation after chronic large myocardial infarction in rats: a comparison of captopril and hydralazine. Circ Res 1989; 64:330-7
154. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz T, Riede UN, Drexler H: Comparative effects of chronic angiotensin-converting enzyme inhibitor and angiotensin II type I receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2 273-82
155. McDonald KM, Garr MD, Carlyle PF, Francis GF, Hauer K, Hunter DW, Parrish T, Stilman A, Cohn JN: The relative effects of alphal adrenoreceptor blockade, converting enzyme inhibitor therapy and angiotensin II subtype I receptor blockade on ventricular remodeling in the dog. Circulation 1994;90:3034-6
156. McDonald, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN: Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-8
157. Johnston CI, Moser V, Sun Y, Fabris B: Changes in cardiac angiotensin converting enzyme after myocardial infarction and hypertrophy in rats. Clin Exp Pharmacol Physiol 1991;18:107-10
158. Weber KT: Snakes and seaweed: a case of the swollen organ. Cardiovasc Res 1995;29:457-62
159. Evers AS, Murphree S, Saffitz JE, Jakschik BA, Needleman P: Effects of endogeneously produced leukotrienes, thromboxane, and prostaglandins on coronary vascular resistance in rabbit myocardial infarction. J Clin Invest 1985;75:992-9
160. Geisterfer AAT, Peach MJ, Owens GK: Angiotensin II induces hypertrophy not hyperplasia of cultured rat aortic smooth muscle cells. Circ Res 1988;62:749-56
161. Paquet JL, Bandomin-Legros M, Brunelle G, Meyer P: Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990; 8:565-72
162. Schelling P, Ganten D, Speck G, Fischer H: Effects of angiotensin II and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV3T3 cells. J Cell Physiol 1979;98:503-13
163. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger Th: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-7
164. Freeman GL, Little WC, Haywood JR: Reduction of left ventricular mass in normal rats by captopril. Cardiovasc Res 1987;21:323-7
165. Nakashima Y, Fouard FM, Tarazi RC: Regression of left ventricular hypertrophy from systemic hypertension by enalapril. Am J Cardiol 1984;53:1044-9
166. Dahlöf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. Am J Hypertens 1992;5:95-110
167. Lievre M, Gueret P, Delair S, Boissel JP, on behalf of the Hycar Study: ACE-inhibitor-induced reduction in left ventricular mass independent of changes in blood pressure in hypertensive patients with left ventricular hypertrophy. Hypertension 1993;22:417
168. Fernandez PG, Snedden W, Idikio H, Fernandez D, Kin BK, Triggle CR: The reversal of left ventricular hypertrophy with control of blood pressure in experimental hypertension. Scand J Clin Lab Invest 1984;44:711-16
169. Clozel JP, Hefti F: Cilazapril prevents the development of cardiac hypertrophy and the decrease in coronary reserve in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1988;11:568-72
170. Brilla CG, Janicki JS, Weber KT: Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991;83: 1771-9
171. Childs TJ, Adams MA, Mak AS: Regression of cardiac hypertrophy in spontaneously hypertensive rats by enalapril and the expression of contractile proteins. Hypertension 1990;16:662-8
172. Linz W, Schölkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens [A] 1989;11(7):267-75
173. Rhaleb NE, Yang XP, Scicli AG, Carretero OA: Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 1994;23(pt 2):865-8
174. Clozel JP, Kuhn H, Hefti F: Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989;7:267-75
175. Odori T, Paskins-Hurlburt A, Hollenberg NK: Increase in collateral arterial endothelial cell proliferation induced by captopril after renal artery stenosis in the rat. Hypertension 1983;5:307-11
176. Crisman RP, Rittmann B, Tomanek RJ: Exercise-induced myocardial growth in the spontaneously hypertensive rat. Microvasc Res 1985;30:185-94
177. Fulton WFM, Thomas CC: The coronary arteries 1965. CC Thomas, Springfield, IL, 1965
178. Gottwik M, Puschmann S, Wuesten B, Nienaber C, Müller KD, Hofmann M, Schaper W: Myocardial protection by collateral vessels during experimental coronary ligation: a prospective study in a canine two-infarct model. Basic Res Cardiol 1984;79:337-43
179. Tomanek RJ, Wessel TJ, Harrison DG: Capillary growth and geometry during long-term hypertension and myocardial hypertrophy in dogs. Am J Physiol 1991;261: H1011-H1018
180. Tomanek RJ, Hovanec JM: The effects of long-term pressure-overload and aging in the myocardium. J Mol Cell Cardiol 1981;13:471-88
181. Messerli FH, Fingerhut R: Left ventricular hypertrophy: an independent risk factor. J Cardiovasc Pharmacol 1991; 17(suppl 4):59-67
182. Schaper W, De Brabander M, Lewi P: DNA synthesis and mitosis in coronary collateral vessels of the dog. Circ Res 1971;28:671-9
183. Meiniger C, Granger H: Mechanisms leading to adenosine-stimulated
184. Quinkler W, Maasberg M, Bernotat-Danielowski S, Lüthe N, Sharma HS, Schaper W: Isolation of heparin-binding growth factors from bovine, porcine and canine hearts. Eur J Biochem 1989;181:67-73
185. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield L, Heine V, Liotta L, Falanga V, Kehr JH, Fauci AS: Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-71
186. Casscells W, Speir E, Sasse J, Klagsbrun M, Allen P, Lee M, Calvo B, Chiba M, Haggroth L, Folkman J, Epstein S: Isolation, characterization, and localization of heparin-binding growth factors in the heart. J Clin Invest 1990; 85:433-41
187. Adair T, Gay WJ, Mantani JP: Growth regulation of the vascular system: evidence for a metabolic hypothesis. Am J Physiol 1990;259:R393-R404
188. Linz W, Martorana PA, Schölkens BA: Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 1990;15:99-109
189. Rösen P, Eckel J, Reinauer H: Influence of bradykinin on glucose uptake and metabolism studies in isolated cardiac myocytes and isolated perfused hearts. Physiol Chem 1983;364:431-8
190. Metsärinne KP, Stoll M, Gohlke P, Paul M, Unger Th: Angiotensin II is antiproliferative for coronary endothelial cells in vitro. Pharm Pharmacol Lett 1992;2: 150-2
191. Stoll M, Lamberty V, Gohlke P, Metsärinne KP, Unger Th: Capillary growth induced by ACE inhibitors: in vivo and in vitro studies. In Schölkens BA, Unger Th: ACE inhibitors, endothelial function and artherosclerosis. Media Medica, Amsterdam, 1993
192. Morbidelli L, Parenti A, Granger HJ, Ziehe M, Ledda F: Activation of DNA synthesis and inositol-phosphate turnover in coronary venular endothelial cells exposed to bradykinin. Pharmacol Res 1993;25(suppl 2): 150-1